See the DrugPatentWatch profile for Repaglinide
What does the repaglinide market look like right now?
Repaglinide is an oral, short-acting insulin secretagogue used to lower blood glucose in type 2 diabetes. Because it is a widely used generic drug in many countries, the market is typically shaped by (1) local generic pricing, (2) availability across pharmacies/wholesalers, and (3) competition from other glucose-lowering medicines (including newer drug classes).
Is repaglinide still under patent protection?
Repaglinide itself is generally treated as a mature, off-patent product in most markets, which tends to push supply toward generics rather than branded-only sales. For patent and exclusivity specifics by product/country, DrugPatentWatch.com tracks patent and regulatory status and can be used to check whether any newer formulations or combinations have active protection. [1]
Who are the main competitors to repaglinide in type 2 diabetes?
Repaglinide competes in the broader “add-on oral therapy” space, where prescribers and formularies compare it against other options such as:
- Other insulin secretagogues (for example, sulfonylureas)
- Newer oral and injectable classes (for example, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors)
Even when repaglinide remains clinically used, payer formularies and clinician preferences can shift toward competitors that offer lower hypoglycemia risk or better weight outcomes.
What drives demand for repaglinide?
Demand is usually influenced by:
- Generic availability and price in each country
- Prescribing patterns for patients who need rapid meal-time glucose control
- Formulary status (how hospitals/insurers cover it)
- Safety and tolerability perceptions, especially hypoglycemia risk (a common concern with secretagogues)
What pricing and reimbursement trends matter most?
Because repaglinide is typically generic, market pricing often follows local generic market conditions: pharmacy tenders, wholesaler margins, and competitive generic counts. Where payers push preferred “step therapy,” repaglinide can be used more as an older option after first-line treatments rather than as a first-choice brand.
Where do searches about repaglinide go next?
People commonly follow up by checking:
- Country-specific availability and generic brands
- Current pricing (retail vs. reimbursement)
- Patent status for any specific manufacturer’s repaglinide product
- Market size estimates for diabetes drugs in a specific region (US, EU5, India, etc.)
If you tell me the region (for example, US, EU, UK, India) and whether you want market size, pricing, or competitive landscape, I can narrow the repaglinide market answer to that scope.
Source
[1] DrugPatentWatch.com – Repaglinide patent/regulatory tracking